• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

幽门弯曲菌对西咪替丁、硫糖铝、铋及十六种抗生素的体外敏感性

In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics.

作者信息

Andreasen J J, Andersen L P

出版信息

Acta Pathol Microbiol Immunol Scand B. 1987 Apr;95(2):147-9. doi: 10.1111/j.1699-0463.1987.tb03103.x.

DOI:10.1111/j.1699-0463.1987.tb03103.x
PMID:3591312
Abstract

The in vitro susceptibility of recent Danish human clinical isolates of Campylobacter pyloridis to cimetidine, sucralfate, bismuth subsalicylate and sixteen antimicrobial agents was determined by an agar-dilution technique. Benzylpenicillin was the most active drug (MIC90 = 0.1 microgram/ml); ampicillin, erythromycin, gentamicin and ciprofloxacin were slightly less active. All strains were resistant to 100 micrograms sulfamethizole, and nalidixic acid also had little activity on weight basis. Of the three anti-peptic ulcer drugs, bismuth subsalicylate was most active (MIC90 25 micrograms/ml), but sucralfate and cimetidine also had antibacterial activity, although only little (MIC90 3200 micrograms/ml).

摘要

采用琼脂稀释技术测定了近期丹麦人幽门弯曲菌临床分离株对西咪替丁、硫糖铝、次水杨酸铋和16种抗菌药物的体外敏感性。苄青霉素是最有效的药物(MIC90 = 0.1微克/毫升);氨苄青霉素、红霉素、庆大霉素和环丙沙星的活性稍低。所有菌株对100微克磺胺甲噻二唑耐药,萘啶酸按重量计活性也很低。在三种抗消化性溃疡药物中,次水杨酸铋活性最高(MIC90为25微克/毫升),但硫糖铝和西咪替丁也有抗菌活性,尽管活性很低(MIC90为3200微克/毫升)。

相似文献

1
In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics.幽门弯曲菌对西咪替丁、硫糖铝、铋及十六种抗生素的体外敏感性
Acta Pathol Microbiol Immunol Scand B. 1987 Apr;95(2):147-9. doi: 10.1111/j.1699-0463.1987.tb03103.x.
2
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.幽门弯曲菌临床分离株对11种抗菌药物的敏感性
Antimicrob Agents Chemother. 1985 Dec;28(6):837-8. doi: 10.1128/AAC.28.6.837.
3
Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents.幽门螺杆菌临床分离株对24种抗菌和抗溃疡药物的敏感性。
Eur J Epidemiol. 1988 Jun;4(2):154-7. doi: 10.1007/BF00144743.
4
Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro--an ultrastructural study.幽门弯曲菌在体外对抗生素、铋剂和抑酸剂的反应——一项超微结构研究。
J Med Microbiol. 1987 Dec;24(4):343-50. doi: 10.1099/00222615-24-4-343.
5
Antibacterial activity of sucralfate and bismuth subsalicylate in simulated gastric fluid.硫糖铝和碱式水杨酸铋在模拟胃液中的抗菌活性。
Eur J Clin Microbiol. 1987 Apr;6(2):216-7. doi: 10.1007/BF02018225.
6
The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.抗生素和抗溃疡药物对幽门弯曲菌的最低抑菌浓度和杀菌浓度。
J Antimicrob Chemother. 1986 Mar;17(3):309-14. doi: 10.1093/jac/17.3.309.
7
The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori.
Zentralbl Bakteriol. 1989 Sep;271(3):304-10. doi: 10.1016/s0934-8840(89)80028-3.
8
In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).枸橼酸铋与多种抗菌剂对幽门弯曲菌(幽门螺杆菌)的体外协同活性。
Antimicrob Agents Chemother. 1987 Sep;31(9):1429-30. doi: 10.1128/AAC.31.9.1429.
9
Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis.铋对幽门弯曲菌定植及胃炎的抗菌作用
Digestion. 1987;37 Suppl 2:16-30. doi: 10.1159/000199555.
10
In vivo susceptibility of Campylobacter pylori.幽门螺杆菌的体内易感性。
Am J Gastroenterol. 1989 Mar;84(3):233-8.

引用本文的文献

1
Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: importance of medium, inoculum, and incubation time.230株幽门螺杆菌的药敏试验:培养基、接种物和孵育时间的重要性
Antimicrob Agents Chemother. 1997 Dec;41(12):2634-9. doi: 10.1128/AAC.41.12.2634.
2
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.用于根除幽门螺杆菌感染的药物的风险效益评估。
Drug Saf. 1996 Jul;15(1):30-52. doi: 10.2165/00002018-199615010-00003.
3
Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents.
幽门螺杆菌临床分离株对24种抗菌和抗溃疡药物的敏感性。
Eur J Epidemiol. 1988 Jun;4(2):154-7. doi: 10.1007/BF00144743.
4
Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori.六种新型氟喹诺酮类药物及其他口服抗菌药物对幽门螺杆菌的体外比较活性
Antimicrob Agents Chemother. 1989 Jan;33(1):108-9. doi: 10.1128/AAC.33.1.108.
5
Campylobacter pylori and gastroduodenal disease.幽门螺杆菌与胃十二指肠疾病
Clin Microbiol Rev. 1990 Jan;3(1):1-12. doi: 10.1128/CMR.3.1.1.